Dr. DeAngelo Discusses Ongoing Trials in AML

Daniel J. DeAngelo, MD, PhD
Published: Tuesday, Feb 27, 2018



Daniel J. DeAngelo, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses ongoing trials of patients with acute myeloid leukemia (AML).

Investigators are researching targeted approaches for patients with relapsed/refractory AML. For patients with IDH1/2 mutations, physicians are focusing on a combination therapy. Using venetoclax (Venclexta) to target BCL-2 is an additional study that is being researched, says DeAngelo.

There is a variety of phase I studies looking at CD33-directed therapy, CD123-directed therapy, and chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy has seen success in other hematologic malignancies, with 2 FDA approvals of tisagenlecleucel (Kymriah) in acute lymphocytic leukemia and axicabtagene ciloleucel (Yescarta) in patients with relapsed or refractory non-Hodgkin lymphoma.
 


Daniel J. DeAngelo, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses ongoing trials of patients with acute myeloid leukemia (AML).

Investigators are researching targeted approaches for patients with relapsed/refractory AML. For patients with IDH1/2 mutations, physicians are focusing on a combination therapy. Using venetoclax (Venclexta) to target BCL-2 is an additional study that is being researched, says DeAngelo.

There is a variety of phase I studies looking at CD33-directed therapy, CD123-directed therapy, and chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy has seen success in other hematologic malignancies, with 2 FDA approvals of tisagenlecleucel (Kymriah) in acute lymphocytic leukemia and axicabtagene ciloleucel (Yescarta) in patients with relapsed or refractory non-Hodgkin lymphoma.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x